Overview

Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-09-22
Target enrollment:
Participant gender:
Summary
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.
Phase:
PHASE2
Details
Lead Sponsor:
Rapport Therapeutics Inc.